The idea of paying for a drug only if it works has long been considered by insurers and healthcare funders as the optimal solution, and has also been embraced by the drug industry as a means of improving product marketing. However, before this strategy can be rolled out widely it needs to be established whether it really adds value for society, the industry and most of all patients.Find out :https://www.credifin-nederland.nl/diensten/no-cure-no-pay-incasso/

A no cure, no pay approach would benefit the authorities by promoting rational pharmacotherapy. It would also increase the attractiveness of a drug to the pharmaceutical industry, which is currently in a difficult position due to its low sales. However, a no-cure, no-pay strategy must not be used as cheap marketing. A clear definition of the conditions under which this policy will apply and a discussion on ethical and practical guidelines are needed.

Debt Recovery Simplified: Exploring the No Cure No Pay Model

Banning no cure, no pay in the out-of-court context will lead to a flood of useless actions and will channel more work to overburdened tribunals. This is a proposal that does not seem to be in touch with or adapted to everyday reality.

Breyta, a debt collection agency operating on a No Cure No Pay basis, has a proven track record and offers the following advantages to clients: